Baby Rabbit Complement
Baby rabbit serum (C12CA) used as a source of complement in a complement bactericidal assay.
Image caption:
Killing of S. Typhimurium by total IgG, IgM and IgA from HIV-uninfected and HIV-infected sera.
Log growth phase S. typhimurium D23580 was added to a mixture of the purified antibodies and 75% BRS. The log10 proportion of the starting number of bacteria remaining after 180 minutes was determined on LB agar. To obtain total antibody of each isotype (IgG, IgM and IgA), serum was incubated sequentially with combinations of human IgA and IgM affinity matrices and protein G affinity matrix to remove IgA, IgM and IgG respectively. Sera used were HIV-uninfected (HIV-ve bactericidal, n = 3), HIV-infected bactericidal (HIV+ve bactericidal, n = 4) and HIV-infected inhibitory (HIV+ve inhibitory, n = 5) sera. Each line represents killing by purified total IgG, IgM or IgA antibodies from one serum. Data shown are from a single representative experiment, where each of the three independent experiments was performed in technical triplicates.
From: Goh YS, Necchi F, O'Shaughnessy CM, Micoli F, Gavini M, Young SP, et al. (2016)
Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
PLoS Negl Trop Dis 10(4): e0004604.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Baby rabbit complement serum preparation is intended for use as a source of rabbit complement for cytotoxicity studies.
Product Details
- Product Form
- Baby rabbit serum - lyophilised
- Reconstitution
- Pack Size: 1 mlReconstitute with 1 ml ice cold distilled waterPack Size: 2 mlReconstitute with 2ml ice cold distilled water
- Preservative Stabilisers
- None present
Storage Information
- Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC for 1 hour or aliquot and store at -70oC for longer.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the product. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- See label for expiry date
More Information
- Regulatory
- For research purposes only
Applications of Baby Rabbit Complement
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Functional Assays 1 | |||
| Immunoassay |
- 1 This product is not sold as sterile but can be sterilized by filtration if necessary. It is preferable to dilute the complement to a final working concentration before filtration in order to minimize loss of volume.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Instructions For Use
- Use within one hour of reconstitution, keeping on ice throughout.
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Product Specific References
References for Baby Rabbit Complement
-
Council of Europe. (1983) Essential aspects of tissue typing: Preparation, use, storage of reagents and standardisation of complement.
European Health Committee, Strasbourg, ISBN 92-871.224-4. -
Edited by J.G.Ray. (1979) NIAID Manual of tissue typing techniques.
Publication No. NIH-80-545. -
Anderson, L.D. Jr et al. (1999) Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Cancer Res. 59 (7): 1525-30. -
Mason, J.C. et al. (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Circ Res. 91 (8): 696-703. -
Lidington, E.A. et al. (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.
Blood. 96 (8): 2784-92. -
De clercq, L. et al. (1997) An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue.
J Anim Sci. 75 (7): 1791-7. -
Hung, M.C. et al. (2011) The Neisseria meningitidis Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate.
Infect Immun. 79: 3784-91. -
Lee, S.J. et al. (2012) Identification of a common immune signature in murine and human systemic Salmonellosis.
Proc Natl Acad Sci U S A. 109 (13): 4998-5003. -
Goh, Y.S. & MacLennan, C.A. (2013) Invasive African nontyphoidal Salmonella requires high levels of complement for cell-free antibody-dependent killing.
J Immunol Methods. 387 (1-2): 121-9. -
Li, S.H. et al. (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells.
Circulation. 109: 833-6. -
Hyams, C. et al. (2010) Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype.
Infect Immun. 78: 716-25. -
Newcombe, J. et al. (2004) Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.
Infect Immun. 72: 338-44. -
Mason, J.C. et al. (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.
Am J Physiol Cell Physiol. 282: C578-87. -
Sancho, D. et al. (2006) CD69 targeting differentially affects the course of collagen-induced arthritis.
J Leukoc Biol. 80: 1233-41. -
Hung MC et al. (2013) The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential.
MBio. 4 (2): pii: e00041-13. -
Goh YS et al. (2016) Bactericidal Immunity to Salmonella in Africans and Mechanisms Causing Its Failure in HIV Infection.
PLoS Negl Trop Dis. 10 (4): e0004604. -
Sawant S et al. (2016) Establishment of 3D Co-Culture Models from Different Stages of Human Tongue Tumorigenesis: Utility in Understanding Neoplastic Progression.
PLoS One. 11 (8): e0160615. -
Humbert MV et al. (2016) Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of Neisseria meningitidis.
PLoS One. 11 (8): e0160403.
